The European Society of Cardiology’s 2014 Annual Congress was described as having the ‘strongest scientific program yet’ by Professor Keith Fox, the program chair. With a focus on innovation and the heart; 27 clinical Hot Line studies, 15 clinical trial updates, four new guidelines, and 4,597 abstracts were presented at the world’s leading cardiovascular disease conference.
PARADIGM-HF: strength of LCZ696’s outcomes data suggests a new paradigm in the treatment of heart failure. With such promising morbidity and mortality data relative to the gold-standard therapy, LCZ696 has the potential to achieve blockbuster status in heart failure.
SOLID-TIMI: darapladib fails to meet primary endpoint in SOLID-TIMI 52 ACS trial after previous failure in chronic CHD. Unfortunately, targeting Lp-PLA2 has not translated into clinically meaningful results, and it is likely that darapladib’s development for cardiovascular disease will be discontinued.
ODYSSEY trials: alirocumab data demonstrate strong impact on lipid lowering and suggest CV outcomes benefit as the PCSK9 inhibitor class’s first-to-market race heats up.